Gastrointestinal & Liver Disease
When you make a donation to the MMRF, you leave a legacy that will impact the health and well-being of people for years to come. Donations of any amount make a difference, and by giving to the MMRF you support the advance of medicine in a wide variety of fields, from pediatrics to geriatrics.
Make a difference, donate today!
HIV/AIDS Research
Dr. Keith Henry, Research Director of HCMC HIV/AIDS Program collaborates with and is supported by Dr. Ronald Schut the HCMC HIV/AIDS Program Director. The HIV/AIDS team unites to improve the care of persons living with HIV. The HCMC HIV/AIDS program sees more HIV infected patients than any other clinic in Minnesota.
While Dr. Keith Henry is studying new drugs, strategies and searching for answers to this devastating disease, his goal is that every HIV infected person live a quality life.
Dr. Henry's expansive experience and cutting edge style in research provides patients with opportunities to enroll in clinical trials. These trials often allow the participants access to the newest therapies that are available only in a research setting. There are drugs "in the pipeline" that don't yet have FDA approval, but look very promising that can be offered to study participants through clinical trials.
Current Research
The HIV/AIDS Research Program is a Minneapolis Medical Research Foundation (MMRF) designated research program. MMRF HIV/AIDS research supports and collaborates with numerous local and national organizations to study the most applicable, pertinent and cutting edge drugs, strategies and therapies. For more information on the following studies, please contact Bette Bordenave, 612-873-2297 or Edie Gunderson, 612-873-7678.
HCMC HIV/AIDS Research Group
The Smart Study - (closed to enrollment) Strategies for Management of Anti-Retroviral Therapy. The purpose of the Smart Study is to compare the long-term clinical consequences of two strategies of antiretroviral management. This study is designed to look at these two different ways of treating HIV and find out which way is most effective and safe for patients over a long period of time. Half of the participants will be randomized into the Viral Suppression arm; a strategy that will use antiretroviral medications continuously to suppress the HIV levels in the blood. The other half of the participants will be randomized into the Drug Conservation arm, a strategy that will use antiretroviral therapy only when the CD4 count goes to 250 or below. This study will enroll 6,000 HIV patients worldwide over the next three years.
The SUN Study - (closed to enrollment) Study to Understand the Natural History of HIV and AIDS. Primary objective of this study is to determine the occurrence and risk factors for non-AIDS defining conditions in HIV-infected patients who are receiving regular HIV and other medical care. The SUN Study will be evaluating HIV primary prevention through screening; treatment and counseling about STDs and HIV risk behaviors. At least 500 participants who are relatively early or mid-point in the course of their HIV infection and treatment will be monitored by various tests. Regular Dexa scanning for bone and fat problems, initial cardiovascular, renal, liver and other tests will be utilized in managing participants care.
BMS – (Open for enrollment) Research study to evaluate the I50L substitution among subjects experiencing virologic failure while on an atazanavir-containing HAART regimen The study only requires one visit which includes a blood draw for resisitance testing , a CD4 cell count, and a viral load measurement.
Pfizer - CCR5 Antagonist, UK-427Trial (closed to enrollment) – A4001027 will examine whether UK-427,857, added to Optimized Background Therapy (OBT) provides an additional reduction in plasma HIV-1 RNA compated to OBT alone. The primary endpoint is a change from baseline to 48 weeks in HIV-1 RNA. An interim analysis is performed at week 24. Secondary endpoints include percentage of patients with fewer than 50/400 copies of HIV-1 RNA per mL of plasma, time to loss of virological response, change in CD4 and CD8 counts, changes in genotype, phenotype and/ or tropism in treatment failures and % with AIDS-defining illness.
TheraTechnologies (closed to enrollment)- Assessing the efficacy and safety of 2 MG dose of TH9507, a growth hormone releasing factor analog, in HIV patients with abdominal fat accumulation.
Keith Henry, MD
Director, HIV/AIDS Clinical Research Program
Dean Tsukayama
Infectious Diseases
Bette Bordenave, RN
Research Coordinator
Edie Gunderson, LPN
Research Coordinator
©2008 Minneapolis Medical Research Foundation
MMRF Webmaster
Last Modified:
June 6, 2008
